Peptide Fat Loss Research Rankings: The Definitive Leaderboard

How This Leaderboard Is Scored

Every compound here is scored across four criteria: evidence tier (human RCT scores highest, then small human studies, then animal, then in-vitro), sample size, mechanistic clarity (how well researchers understand the pathway driving the effect), and reproducibility across independent labs. A peptide with one rodent study and no proposed mechanism sits near the bottom regardless of how often it appears in forums.

The leaderboard covers compounds that are either peptides by structure or peptide-derived analogs. That means GLP-1 receptor agonists qualify, as do growth-hormone-releasing peptides and fragment analogs. Compounds with an FDA-approved branded drug form are noted clearly, because the research-chemical versions sold online are not approved drugs and carry a different regulatory and safety profile entirely.

Scores are presented as composite ratings out of 10. A 9 or 10 requires multiple large RCTs with replicated outcomes. A 5 to 7 means solid animal data plus at least one small human study. Below 5 means the evidence is almost entirely preclinical or mechanistic speculation.

Tier 1: The Heavy Hitters With Human RCT Data

Semaglutide earns the top spot. The STEP 1 trial (2021, New England Journal of Medicine, n=1,961) showed participants receiving 2.4 mg weekly lost a mean 14.9% of body weight over 68 weeks versus 2.4% on placebo. Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The branded injectable forms Wegovy and Ozempic are FDA-approved for specific indications. Research-chemical semaglutide is not approved. Research score: 9.5/10.

Tirzepatide follows closely. It acts on both GLP-1 and GIP receptors, a dual mechanism that gives it a distinct pharmacological profile from semaglutide. The SURMOUNT-1 trial (2022, New England Journal of Medicine, n=2,539) reported up to 20.9% mean weight reduction at the highest dose studied over 72 weeks. Zepbound and Mounjaro are the FDA-approved branded forms. The research-chemical version is not approved. Research score: 9.3/10.

Both compounds have extensive mechanistic literature explaining how GLP-1 and GIP receptor activation affects hypothalamic satiety signaling, adipocyte lipolysis, and insulin sensitivity. That mechanistic depth, combined with trial scale, is why they sit alone in Tier 1.

Tier 2: Strong Preclinical Signals, Limited Human Data

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176 to 191) studied specifically for lipolytic effects. A 2001 study published in the American Journal of Physiology found that AOD-9604 stimulated fat breakdown in obese rodent models without affecting blood glucose or IGF-1 levels, which distinguished it from full-length HGH. Human trials were conducted in the early 2000s by Metabolic Pharmaceuticals, but the compound never reached regulatory approval, and the human data from those trials showed modest and inconsistent results. Research score: 6.2/10.

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog that extends the half-life of endogenous GHRH. A 2006 study in the Journal of Clinical Endocrinology and Metabolism (n=65) showed sustained GH and IGF-1 elevation over multiple days after a single injection. Elevated GH is associated with increased lipolysis in adipose tissue, but the 2006 trial did not measure body composition as a primary endpoint. The fat-metabolism link is mechanistically plausible but not directly confirmed in a human RCT. Research score: 5.8/10.

Tesamorelin sits in a unique position. It is a GHRH analog with an FDA-approved form (Egrifta) specifically for HIV-associated lipodystrophy, meaning the approval is narrow and condition-specific. A 2010 RCT in the New England Journal of Medicine (n=412) showed significant visceral adipose tissue reduction in that population. Because the approval and the RCT data are tied to a specific disease context, tesamorelin's score reflects strong evidence in a narrow population rather than general fat metabolism. Research score: 7.1/10.

Tier 3: Animal Data Dominates, Human Evidence Thin

Ipamorelin is a selective growth hormone secretagogue that stimulates GH release with minimal effect on cortisol or prolactin in animal studies. A 1998 paper in the European Journal of Endocrinology characterized its selectivity profile in rats. The lipolysis connection is indirect: GH elevation promotes fat mobilization, and ipamorelin raises GH. No published human RCT has measured body composition as a primary outcome. Research score: 4.9/10.

GHRP-6 and GHRP-2 are older ghrelin mimetics with a larger body of animal literature than ipamorelin. GHRP-6 notably stimulates appetite via ghrelin receptor activation, which complicates its positioning in a fat-loss context. Some researchers have studied its GH-mediated lipolytic potential, but the appetite-stimulating side effect creates a mechanistic tension that limits its ranking here. Research score: 4.4/10.

BPC-157 has a growing preclinical literature, mostly in rodent models, covering wound healing, gut integrity, and some metabolic markers. A 2020 review in Current Pharmaceutical Design summarized animal findings but noted the absence of human clinical trials. Its fat-metabolism mechanism is not well defined compared to GH-axis peptides or GLP-1 agonists. Research score: 3.8/10.

What Separates the Top of the Board From the Bottom?

The gap between Tier 1 and Tier 3 comes down to three things: trial scale, endpoint specificity, and mechanistic confirmation in humans. Semaglutide and tirzepatide were studied in trials enrolling thousands of participants with body weight as the primary endpoint. Tier 3 compounds were mostly studied in dozens of rodents with fat metabolism as a secondary or inferred outcome.

Mechanistic clarity also matters for scoring. When researchers can point to a receptor, a downstream signaling cascade, and a measurable physiological output confirmed in human tissue or human trials, the score goes up. GLP-1 receptor binding, cAMP elevation, reduced gastric emptying, and hypothalamic satiety signaling are all documented in humans for semaglutide. For GHRP-6, the chain from GH pulse to net fat loss in humans is assumed more than measured.

Reproducibility across independent labs is the final separator. Semaglutide's effects have been replicated in STEP 1, STEP 2, STEP 3, and STEP 4 trials across different populations. AOD-9604's human results were produced by a single company's internal program and were never independently replicated at scale. Independent replication is a core criterion on this board, and it shows in the scores.

The Full Standings at a Glance

Here is the condensed leaderboard with scores and primary evidence basis for each compound.

Scores reflect the state of published research as of mid-2025. New trials can move a compound up the board quickly, particularly if a Tier 2 compound completes a large RCT with body composition as a primary endpoint. ClinicalTrials.gov currently lists several ongoing studies on GHRH analogs and GH secretagogues that could shift rankings within the next two to three years.

• 1. Semaglutide: 9.5/10 | Multiple large RCTs | FDA-approved branded forms (Wegovy, Ozempic); research-chemical form not approved
• 2. Tirzepatide: 9.3/10 | Multiple large RCTs | FDA-approved branded forms (Zepbound, Mounjaro); research-chemical form not approved
• 3. Tesamorelin: 7.1/10 | One large RCT in HIV lipodystrophy | FDA-approved form (Egrifta) for narrow indication only
• 4. AOD-9604: 6.2/10 | Strong rodent data, inconsistent small human trials | No approval
• 5. CJC-1295: 5.8/10 | One small human study on GH/IGF-1, no body composition RCT | No approval
• 6. Ipamorelin: 4.9/10 | Rodent selectivity data, no human body composition RCT | No approval
• 7. GHRP-6: 4.4/10 | Rodent GH data, appetite-stimulating mechanism complicates fat-loss framing | No approval
• 8. BPC-157: 3.8/10 | Rodent models only, fat metabolism mechanism unclear | No approval